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Abstract
Eosinophils are immune response cells located in the peripheral blood, bone 
marrow, and lymph nodes, among others; an increase in the number of eosinophils 
in the peripheral blood above 5000/mm3 is associated with conditions ranging from 
infections (bacterial and parasitic) and allergy (asthma, rhinitis, or drugs), even 
neoplasms. Various study groups have classified them according to their etiology, 
thus facilitating their diagnosis and treatment. The WHO divides them as primary 
and secondary and also considers the number of eosinophils/mm3 and the involve-
ment of white organs, while others have divided them into intrinsic and extrinsic. 
The former include mutations in the pluripotential hematopoietic cells, which lead 
to chronic myeloid leukemias with clonal expansion of eosinophils and extrinsic 
ones where the changes are related to a TH2 response activated by different cyto-
sines such as IL-5. Current treatments are specifically aimed at modifying the 
clonal expansion of eosinophils with corticosteroids, hydroxyurea, interferon (peg) 
alpha, imatinib, among others, and bone marrow transplantation, while in extrinsic 
alterations corticosteroids and IL inhibitors are used −5 (mepolizumab).
Keywords: eosinophilia, hypereosinophilic syndrome, interleukin-5, diagnosis, 
treatment
1. Introduction
1.1 Characteristics: morphological, physiological, origin, immunological 
regulation, and distribution of eosinophil
Eosinophils are leukocytes (white cells) found in the peripheral blood, hemato-
poietic, lymphatic organs, the bone marrow, spleen, and thymus, and can migrate 
to connective tissues and digestive tract; they are part of the group of leukocytes 
called granulocytes, along with basophils and neutrophils. They were described 
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by P. Ehrlich in 1879 calling them eosinophils because their acidic granules in the 
cytoplasm were stained by their affinity dye aniline-eosin giving them the form of 
red-orange ammunition observed by optical microscopy: They are rounded cells 
from 8 to 15 μm in diameter, with a bilobed core with a fine nuclear bridge joining 
both lobes [1].
Identification and quantification.
Methodology: Manual count in Neubauer chamber and automatic hematol-
ogy analyzer using impedance and colorimetry and flow cytometry CD16 
(FcƳRIII-CD16). Under normal conditions peripheral blood eosinophils represent 
1–5% of total leukocytes, with an upper limit of 0.4 × 109 L,, the absolute eosino-
philic count (AEC) of 350–500/mm3 and in children is greater than 0.75 × 109 L, 
increasing the number of eosinophils (eosinophilia) to more than 3–5 times which 
is indicative of an activity of infectious, parasitic, allergic, and eosinophilic and 
hypereosinophilic disorders [1–5].
They originate in the bone marrow, by a process of maturation and differentia-
tion that lasts approximately 8 days (hematopoiesis) from a pluripotential precursor 
cell (stem cell) differentiating itself as myeloid granulocytic line, under the influ-
ence of IL-3, IL-4 - granulocytic colony stimulation factor (GM-CSF) of eotaxin; 
evolving toward a mixed eosinophil-basophilic precursor and then differentiating 
toward eosinophils by action of IL-3, GM-CSF, and especially IL-5, they have a 
survival of 6–12 hours before moving to tissues where they remain between 2 and 
5 days; once there is a stimulus, they respond by exercising their multiple functions 
regulated by T lymphocytes (Figure 1) [1, 2, 6].
The text begins with: Its main functions are the defense against parasites, 
helminths, nematodes, participate in allergic responses, inflammatory processes, 
restoration, and tissue repair; since they have specific chemotactic receptors on 
their membrane, eotaxin, cytokines (IL-3 -IL-5 and GM-CSF), eosinophil chemo-
tactic factor of anaphylaxis (ECF-A); and nonspecific such as f MLP (from the wall 
of bacteria), complement activation products (C3a, C5a, C6, and C7), platelet-
activating factor (PAF), leukotrienes (LTB 4 and LTD 4), histamine and IL-8. 
Diapedesis is mainly performed by integrins to adhere to the vascular endothelium 
Figure 1. 
Scheme representing hematopoiesis, origin of eosinophil and its main functions associated with eosinophilic 
disorders. Molecules expressed on its surface (FcεRI-CD23-IgE). CCR4, CD88,H4R. Adhesion molecules: 
CD11b, CD11c, CD62L, and chemokines that attract eosinophils from blood to tissues [3, 7].
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(e.g., LFA-1-ICAM-1, the VLA-VCAM-1) and other multiple antibody receptors: 
IgA (Fc α R1-CD89), (FcεRIII-CD23-IgE), (FcƳεRI-degranulation), (FcƳRI-
CD64-IgG1, IgG3 respiratory burst induction of microbial death), (FcƳA-CD32-Ig 
G1-degranulation), (FcƳRIIB-CD32-IgG1-No Phagocytosis, inhibition of cellular 
activity) (Figure 1) [2, 6, 8].
Granular content: Eosinophil mature contains in its cytoplasm primary granules 
rich in phospholipase A, rich in crystalline proteins of Charcot-Leyden-specific sec-
ondary granules containing the major or main basic protein (MBP), the eosinophilic 
peroxidase (EPO), eosinophilic protein (ECP)), and eosinophil-derived neurotoxin 
(EDN) that also appears in basophils and neutrophils; its response capacity is less 
than 1 hour, small granules containing arylsulfatase B and acid phosphatase and five 
lipid bodies main source of arachidonic acid, can be presenting cells, proliferation 
of T lymphocytes and basophils are capable of deliberating more than 35 cytokines, 
chemokines, and growth factors (Figure 1) [5, 9].
2. Diseases and classification
The severity of eosinophilia has been arbitrarily divided into mild (AEC from 
the upper limit of normal to 1500/mm3), moderate (AEC 1500–5000/mm3), and 
severe (AEC >5000/mm3).
The classification of eosinophilic diseases was revised in 2008 and reaffirmed in 
2016. In 2017 its diagnosis, risk stratification (prognosis), and management (treat-
ment) proposed by the World Health Organization were covered [10].
Eosinophilic diseases can be classified in two types: primary, intrinsic hematol-
ogy due to clonal disorders, and secondary, extrinsic or reactive disorders to an 
external cause that cause damage to different organs. Primary eosinophilias or 
clonal disorders can be diagnosed by studying the blood and bone marrow by the 
following methods: standard cytogenetics, molecular biology with monoclonal 
antibodies, flow cytometry, in situ hybridization, and evaluation of T cell clonality.
The major category of primary diseases corresponds to myeloid/lymphoid neo-
plasms with eosinophilia and rearrangements PDGFRA, PDGFRB, or FGR1; with 
PCMiJAK2 and MPN, a subtype of chronic eosinophilic leukemia or not specified by 
CEL-NOS, there is another lymphoid-eosinophilic variant of aberrant T cell clone.
The modern definition of hypereosinophilic syndrome (HES) is a vestige of the 
historical criteria outlined by Chusid and colleagues in 1975: The absolute eosinophil 
count is >1500/mm3 for more than 6 months, and tissue damage is present [10, 11].
The Working Conference on Eosinophil Disorders and Syndromes proposed a 
new terminology for eosinophilic syndromes. Hypereosinophilia (HE) for persis-
tent and marked eosinophilia (AEC >1500/mm3) in turn, HE subtypes were divided 
into a hereditary (familiar) variant (HEfa); HE of undetermined significance 
(HEus), primary (clonal-neoplastic), HE produced by clonal/neoplastic eosinophils 
(HEn), and secondary (reactive) (HEr) can be considered a provisional diagnosis 
until a primary or secondary cause of eosinophilia is ascertained [12].
To have to a better understanding of the pathogenetic aspects of eosinophilia, 
other classifications of eosinophilic diseases were generated according to the site 
of eosinophilic infiltration associated with organ damage and dysfunction. The 
primary cause of eosinophilia located within the eosinophils (and/or eosinophil 
precursors) themselves or in other cells, similar to allergic diseases, can be divided 
in IgE-mediated (extrinsic) and non-IgE-mediated (intrinsic) diseases; the terms 
extrinsic and intrinsic eosinophilic disorders indicate whether the primary cause of 
eosinophilia is inside or outside the eosinophil lineage [11].
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2.1 Eosinophilic intrinsic disorders
Chronic eosinophilic leukemias belong to a special group of chronic myeloid leu-
kemias, in which eosinophil differentiation is dominant, resulting in blood eosino-
phil counts of greater than 1500/mm3. However, other lineages are also affected, 
because the disease is the result of a mutation in a pluripotent hematopoietic stem 
cell. The chromosomal translocations related to breakpoints on chromosome 8p11 
result in fibroblast growth factor receptor 1 fusion genes with increased kinase 
activity causing the so-called 8p11 syndrome. The increase in tyrosine kinase activ-
ity is caused by gene 1 and the growth factor, and this leukemia has a worse prog-
nosis, which transforms chronic leukemia to an acute, 1–2 years. Another type of 
cause may be the increase in tyrosine kinase by fusion of the platelet growth factor 
alpha receptor genes (PDGFRA). PDGFRA is fused by the Fip1-like 1 (FIP1L1) gene 
as a result of a 4q12.9 chromosome damage. This is both in eosinophils and in other 
hematopoietic lineages such as neutrophils, monocytes, lymphocytes, and mast 
cells. This type of leukemia is pluripotent hematopoietic stem cell which responds 
to the tyrosine kinase inhibitor (imatinib) [10, 11].
Mutations in multipotent myeloid stem cells: In the chronic myeloid leukemias 
with eosinophilia, eosinophils are part of the clone. This is because eosinophil 
differentiation is often not as prominent as other myeloid cells, such as monocytes, 
which also show increased differentiation. Chromosomal translocations related 
to breakpoints on chromosome 5q33 are common and represent the basis for the 
formation of platelet-derived growth factor receptor b (PDGFRB) fusion genes; 
this result increases the tyrosine kinase activity. There are patients with positive 
Philadelphia chromosome who can develop chronic leukemia with eosinophilia due 
to two factors: fusion by breakpoint cluster region-Abelson (ABL) and fusion of 
transcription gene 6 (ETV6). Marked eosinophilia often associated with a cyto-
genetic evolution and other accelerated phases of ABL can occur during an acute 
transformation; ABL may be fused with the transcription factor E26 by means of 
variant ETV6 triggering chronic leukemia [10].
Myelodysplastic syndromes: During hematopoiesis there may be an inefficient 
process in the differentiation of stem cell by mutations, malignant clones producing 
myelodysplastic syndromes that lead to myeloproliferative diseases such as polycy-
themia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. The 
exact molecular genetic abnormalities resulting in eosinophilia in these disorders 
remain to be determined [10, 11].
2.2 Eosinophilic extrinsic disorders
T cell-mediated eosinophilias: The common diseases are allergic rhinoconjunc-
tivitis, bronchial asthma, drug allergic, eosinophilic esophagitis, and atopic der-
matitis. Eosinophilia and IgE production due to the polarization of TH2 cells whose 
causes are extrinsic or external by stimulation of environmental immunogens or 
chemical compounds, which are presented by APC-MHC, stimulating the release of 
pro-inflammatory cytokines (IL4, IL5, and IL13), induce the increase in eosinophils 
of IgE survival, high affinity receptors with PKC activation, cross-linking and 
signaling for histamine release, as well as vasoactive amines that produce inflamma-
tory processes and organ damage [10, 11].
Infectious diseases: TH2 inflammatory responses are induced by helminths; 
these responses are characterized by IgE antibody production and eosinophilia; 
both have been implicated in mediating protective immunity to the parasites. In 
contrast, there is little doubt that eosinophils contribute to tissue damage and 
therefore to the pathogenesis of these infections.
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Viral infections are not common; however, when virus-specific T cells are 
generated in a TH2 environment, they can also release IL-5 and therefore trigger 
eosinophilia. In chronic rhinosinusitis, eosinophilia is related to fungal infections 
with certain molds (e.g., Alternaria) which is present in the nasal and paranasal 
cavities [5, 10, 11].
Autoimmune diseases: Because these diseases are often associated with a TH1-
associated inflammatory response, eosinophilia is not frequent, but in systemic 
sclerosis, levels of major basic protein and extracellular major basic protein deposi-
tions were observed in skin and lung tissues. In primary biliary cirrhosis, eosino-
philia is a distinctive feature that might be useful in the diagnosis of the disease 
[10, 11, 13].
Graft-versus-host diseases: When an allogeneic bone marrow transplant is 
carried out and there are differences in MHC molecule polymorphism, these can be 
recognized by the immune system, and responses can be made against the allo-
antigens, producing graft-versus- host-disease (GVHDs), carrying out a reaction 
antigen antibody, cellular or cytotoxic that produces lysis and destruction in specific 
organs (skin, liver, and gastrointestinal tract mainly).
Drug-induced diseases: Hypersensitivity drug reactions may present in some 
cases increased eosinophils. The manifestations range from maculopapular rashes 
of the skin to severe life-threatening drug reactions with eosinophilia and systemic 
symptoms (DRESS). Drugs and their metabolites can produce hypersensitivity by 
means of mechanisms mediated by APC-MHC TCR pi concept, generating TH2 
polarity or TH1 with memory T cells [10, 11, 13].
There are other subgroups of this syndrome as episodic angioedema and 
hereditary eosinophilia. Where there is evidence of mechanism mediated by IL-5-
producing T cells [5].
Figure 2. 
Diagnostic algorithm for patients with hypereosinophilia. Due to the fact that eosinophilia can occur in 
different pathologies, an exclusion of the unlikely causes for hypereosinophilia is performed, in addition to a 
three-step follow-up treatment with imatinib due to mutation processes that is considered. Laboratory tests 
would be at the discretion of the doctor according to the medical history and the search according to the type of 
response to the genes involved [12].
Cells of the Immune System
6
Severe primary (IL-5) and secondary immunodeficiencies (HIV) are associated 
with eosinophilia when there is polarization of TH2 by the immunogen (allergen) or 
drug (antiretroviral); infections such as tuberculosis are the cause of infections and 
resistance to treatment (Figure 2) [11].
2.3 Treatment of HES and CEL-NOS
Corticosteroids should be considered a first-line treatment, which are potent 
anti-eosinophil agents, effective in producing rapid reductions. Maximal dose was 
1 mg × kg 2 months, with symptom control and reduction of the eosinophil count to 
below 1500/mm3 after 1 month of treatment.
Hydroxyurea is an effective first-line agent for HES which may be used in con-
junction with corticosteroids or in steroid nonresponders. A typical starting dose 
is 500–1000 mg daily which can serve as effective palliative to control leukocytosis 
and eosinophilia but with no proven role in favorably altering the natural history of 
HES or CEL-NOS (Figure 2) [10, 12, 14].
IFN-a has demonstrated hematologic responses and reversion of organ injury 
in patients with HES and CEL-NOS refractory to therapies including prednisone 
and/or hydroxyurea. Remissions have been associated with improvement in clinical 
symptoms and organ disease, including hepatosplenomegaly, cardiac and thrombo-
embolic complications, mucosal ulcers, and skin involvement [5, 10–12].
Figure 3. 
Diagnostic and treatment algorithm based on revised 2016 WHO classification of eosinophilic disorders. 
According to the algorithm, the type of eosinophilia can be monitored according to the cases where other drugs 
other than imatinib should be used, with three pathological options being present: chronic leukemia with 
eosinophilia, idiopathic hypereosinophilia, and lymphocyte variant, all share the administration of imatinib 
and corticosteroids (idiopathic hypereosinophilia and lymphocyte variant) [10].
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Mepolizumab anti-IL-5 antibody is a fully monoclonal IgG antibody that inhibits 
binding of IL-5 chain of the IL-5 receptor expressed on eosinophils [5, 14].
Alemtuzumab is an anti-CD52 monoclonal antibody that has been evaluated in 
idiopathic HES based on expression of the CD52 antigen on eosinophils. In patients 
with refractory HES, alemtuzumab was administered intravenously at a dose of 
5–30 mg once to thrice weekly.
Bone marrow/peripheral blood stem cell allogeneic transplantation has been 
attempted in patients with aggressive disease; a disease-free survival ranging from 
8 months to 5 years has been reported.
Imatinib is a small-molecule tyrosine kinase inhibitor 100 mg per day; it also 
shows activity against platelet-derived growth factor receptor (PDGF-R), c-Kit, 
Abl-related gene (ARG), and their fusion proteins while sparing other kinases 
(Figure 3) [10].
3. Hematologic and neoplastic diseases
Mastocytosis: Develops from a neoplastic proliferation of mast cells. It develops 
from a neoplastic clonal proliferation of mastocytes that accumulate in one or more 
organ systems and are organize as compact cohesive aggregate groups or multifocal 
groups of abnormal mastocytes. This disorder is diverse; it can be found as cutaneous 
lesions that may naturally recede, to highly aggressive neoplasias related with multiple 
organ failure and short outliving. Mastocytosis subtypes are principally characterized 
by the clinical manifestations and the spread of the disease. When cutaneous masto-
cytosis (CM) occurs, mastocyte infiltration is restricted to the skin, whereas systemic 
mastocytosis (SM) includes at least one extracutaneous organ, with or without skin 
lesions. Mastocytosis must be distinguished from mastocyte hyperplasia or from the 
mastocyte activation states, without the morphological or molecular abnormalities that 
characterize neoplastic proliferation [15]. The WHO classification includes seven types:
a. Cutaneous mastocytosis
b. Indolent systemic mastocytosis (ISM)
c. Systemic mastocytosis with associated clonal, hematologic non-mast cell line-
age disease (SM-AHNMD)
d. Aggressive systemic mastocytosis (ASM)
e. Mast cell leukemia (MCL)
f. Mast cell sarcoma (MCS)
g. Extracutaneous mastocytoma
Hypereosinophilic syndrome (HES): It has been described as a condition associ-
ated with persistent eosinophilia in the peripheral blood, organ damage, and exclu-
sion of any other underlying disease or condition that may explain eosinophilia or 
organ damage [4, 16–18]. The diagnostic algorithm must begin with the evaluation 
of peripheral blood hypereosinophilia (HE), defined as a persistent increase of 
blood eosinophils, above 1.5 X 109/L blood [4, 16–18]. The term “tissue HE” has also 
been proposed, and it may be useful in the evaluation and the classification of the 
disorders related to HES [16, 19]. The establishment of an HES diagnosis must be 
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considered: (a) the existence of an underlying disease or condition and (b) the pres-
ence of clinical signs and symptoms or laboratory abnormalities that show organ 
damage induced by HE (HES) [19]. There are four important groups of underlying 
disorders in patients with documented HES:
1. Hematopoietic neoplasias
2. Other neoplasias (non-hematopoietic) (paraneoplastic HE)
3. Common allergic, reactive, or immunological conditions
4. Infrequent clinical syndromes that present HE, including rare hereditary 
disorders [19]
Lymphoid and myeloid leukemias: Many hematologic disorders may present 
eosinophilia, but only a few present clonal (primary) neoplasias, and just a small 
number of neoplasms present HE and organ damage. Myeloid neoplasias that 
present HE include rare acute eosinophilic leukemia types. The most common type 
of chronic leukemia is chronic eosinophilic leukemia (CEL), which is frequently 
associated with the FIP1L1-PDGFRA rearrangement in endomyocardial fibrosis/
thrombosis and other myeloid neoplasias with rearrangements, such as the 8p11 
syndrome [19, 20]. Clonal eosinophilia is frequently observed in advanced cases of 
systemic mastocytosis [19, 21, 22].
Lymphoid neoplasms may present HE, and in most cases, a T cell lymphoma 
is diagnosed. Nevertheless, in such patients with 8p11 syndrome and other rare 
entities, both eosinophils and lymphocytes may be involved in the neoplastic clonal 
processes [19, 21].
Paraneoplastic conditions associated with hypereosinophilia. Different types of 
cancers may be preceded or accompanied by eosinophilia. Cancers associated with 
HE include lung, gastrointestinal tract, pancreas, and thyroid adenocarcinomas, 
gynecologic tumors, and skin cancer. Although pathogenesis is unclear, there is a 
widely accepted hypothesis stating that carcinogenic cells or cancer or the cancer 
microenvironment around fibroblasts produce eosinophilopoietic cytokines [19, 23].
Identification and quantification.
Classic methodology: Clinical manifestations and diagnosis depend on the type 
of disease and other factors, where different organs may be involved in patients 
with HES, for example, skin, gastrointestinal tract, heart, and central nervous 
system.
In order to establish an HES diagnosis, it is recommended to include clinical and 
laboratory parameters, such as:
a. Physical exam of organs and body systems
b. Laboratory exams: white blood cell count (eosinophils, basophils, neutrophils), 
hemoglobin, platelet count, B12 vitamin, hepatic enzymes, kidney function 
tests, and urinalysis
c. Organic functional tests: electrocardiogram, echocardiogram, pulmonary 
function tests, chest computed tomography and radiography, abdominal 
ultrasound, and normal endoscopic study [19]
d. Molecular detection of some translocations, such as TCR, BCR/ABL1, JAK2 
V617F, KITD816V, PDGFRA/PDGFRB, and FGR1
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3.1 Laboratory diagnosis by molecular parameters
Immunoglobulins rearrangements are detected by real-time polymerase chain 
reaction with TaqMan molecular probes, such as TCR, BCR/ABL1, JAK2 V617F, 
KITD816V, PDGFRA/PDGFRB, and FGR1. The most recommended bone marrow 
exams are cytogenetic assays and fluorescence in situ hybridization (FISH)—other 
studies which do not include molecular detection are tissue immunohistochemistry 
and histology (Figure 4) [16].
4. Allergy and hypersensitivity to drugs (DHRs)
The WHO defines an ADR to any predictable noxious reaction that appears at 
therapeutic doses, depends on the doses, and is related to pharmacological actions. 
Other unpredictable reactions: hypersensitivity or allergic (DHRs) associated with 
immunological mechanisms, susceptibility (atopy), and polymorphism (pharmaco-
genetic, MHC-HLA) [24–27].
It is considered as a public health problem due to its high morbidity and mortal-
ity being 20%; hence, the importance of its clinical diagnosis and laboratory tests 
is being considered at all stages of life (prenatal, postnatal, childhood, adolescence, 
adult, and older adult).
4.1 Immune response to drugs in DHRs: haptens, pro-haptens, and TCR pi
Medications are usually non-immunogenic haptens of different types:
Pro-haptens. Drugs are generally non-immunogenic haptens of different types: 
Pro-haptens (non-active reagents) low molecular weight chemicals of less than 
1000 D; examples aromatic, heterocyclic, sulfonamides, OH, halogens, resonance, 
and beta-lactam are processed and presented in the CPA-MHC context and produce 
a humoral response, IgE, IgG and IgM or cellular.
Active reagents: aromatic, polar, with nitrogen, to induce an immune response 
CPA-MHC.
Figure 4. 
Flow diagram to perform real-time PCR. In a simplified way, the preparation of the sample with its 
corresponding primer and the distribution of the samples for its reaction are shown, which can be seen in real 
time by monitoring the amplification as the cycles in the thermal cycler pass.
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Inert TCR pi (pharmacological interaction with immune receptors): Some drugs 
are able to bind non-covalently to TCR pi receptors pre-developed by a previ-
ous immune response to a non-covalently reversible drug and signaling toward a 
response of hypersensitivity and explain the rapid appearance of symptoms, some 
cross reactions to the drug, or its metabolites.
Pi concept and HLA restriction in hypersensitivity: In the pi concept, drugs pri-
marily activate TCR, for example, abacavir associated with the HLA-B * 5701 allele in 
whites, Stevens-Johnson syndrome (SJS) with carbamazepine treatment in Chinese 
associated in patients with the HLA-B * 1502, and HLA-B * 5801 allele in allopurinol-
induced adverse reactions such as SJS and toxic epidermal necrolysis (TEN) [28–31].
4.2 Hypersensitivity and diagnosis
Hypersensitivity is an exacerbated immune response, which produces a clinical 
picture with dermal, systemic disorders, and sometimes sudden death. In 1930 
Coombs systematized these reactions according to the period of time in which the 
symptoms appear, and the dose of challenge has been fundamental to guide the 
diagnosis, treatment, and monitoring. It has many points in common with autoim-
munity, where the antigens are their own; in the case of allergies to medications, the 
antigens are allergens: drugs or metabolic derivatives. Hypersensitivity reactions 
require that the individual has been previously sensitized or exposed to at least the 
antigens in question. The classification of allergic or hypersensitivity reactions into 
four types (I, II, III, and IV) and subsequently Pichler in 2003 proposed the subdi-
vision of type IV into IVa, IVb, IVc, and IVd (Table 1) [28, 29].
4.3 In vitro tests associated with drug and drug eosinophilia: antibiotics, 
nonsteroidal anti-inflammatory drugs (NSAIDs) anticonvulsants, and 
antidiuretics
Modified basophil degranulation (MBD): The test is a basophil activation test 
(BAT) which consists of incubating the basophils in vitro with the suspected drug 
to be carried out: epitope-paratope binding, activating the basophils and caus-
ing degranulation and release of the aforementioned content (specificity 100%, 
sensitivity 84.0%) [28, 29].
CD63 flow cytometry: Basophils with specific IgE when incubated with the sus-
pected drug are activated by Fcε I receptors; high affinity and low affinity cause cross-
linking and protein kinase signal transduction (MAP, PKC) that stimulate expression 
of the receptor (CD63) -gp53 (lysosomal-transmembrane protein tetraspanin LAMP-
31) on the surface of the basophil while the eosinophilic expresses CD23 [30].
Modified leukocyte migration inhibition factor (MLIF) type IV a, b, and c. 
Associated with anaphylactic degranulation: It has been reported that leukocytes 
including basophils (BAT-Chemotaxis) also play a role in directional chemotaxis; 
therefore, when microhematocrits are incubated in Bloom chambers with medica-
tions in two dilutions (1 and 0.1 mg/mL) in an RPMI medium, with negative and 
positive controls, at 37°C, the first (20 min at 2 hours) and delayed migration can 
be measured (4, 6, and 18 hours); the % of MLIF can also be calculated against the 
negative control, as well as the reference values (RV) for MLIF (0–25% inhibition of 
leukocyte migration) [29].
Eosinophilia in the peripheral blood is a common cause in patients who consume 
medications, especially in developed countries, who are monitored and can restrict 
their consumption without changes. However, for the doctor, concern may arise in 
cases of impending hypersensitivity reaction (HSR). Severe HSRs associated with 
peripheral blood may include specific reactions of organs (heart, kidney, liver, 
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lungs, joints, central nervous system, and skin) and adverse skin reactions (SCAR) 
where SJS, TEN, and DRESS are included [32, 33].
Type Type of immune 
response
Clinical symptoms In vitro 
diagnostics
In vivo diagnostics
I Measured by IgE 
eosinophils, mast 
cells, and basophils 
(immediate)
Urticaria
Angioedema
Rhinitis
Bronchospasm
Anaphylaxis
IgE specific 
Serum tryptase 
Cell stimulation 
test (CAST)
BAT(MDB, 
CD63)
Cutaneous tests (prick, 
intradermal)
Challenge tests
Proving tests [Coombs]
II Cytotoxicity 
dependent on IgG 
and IGM antibodies 
(not immediate) 
and complement
Hemolytic
Anemia
Thrombocytopenia
Neutropenia
Autoimmunity
Coombs test
Ab vs. platelets
Ab vs. 
neutrophils
Only challenges to 
the drug can make 
diagnosis but are high 
risk [Coombs]
III Deposit of 
immunocomplexes 
[IgG and IgM] 
(not immediate) 
Complement or 
FcR
Serum disease 
Vasculitis, LES-like 
by medications 
Glomerulonephritis 
drug
C3, C4, ANA, 
ANCA, CCP, 
antithyroid, etc. 
Liver and kidney 
function tests 
Pathological 
anatomy
Biopsies with 
immunofluorescence 
[Coombs]
IVa TH1 (IFNγ), 
TNFα, IL12, and 
macrophages (late)
Contact dermatitis Lymphocyte 
transformation 
test (LT or BT), 
MLIF, cytotoxic 
T lymphocyte 
precursors 
(CTLp), 
cytokines 
(ELISA, PCR)
Patch tests [Pichler]
IVb TH2 (IL-4, IL5, 
IL13) eosinophils
Maculopapular 
eruptions (MPE) 
with eosinophilia 
(DRESS)
CBC with check 
eosinophil 
cellularity, 
atypical 
lymphocytes 
MLIF, BT, LT
Patch tests [Pichler]
IVc CLT, CD4/
CD8 (perforin, 
granzyme B, Fas L)
Contact dermatitis, 
maculopapular, 
and bullous 
diseases(SJS), TEN
MLIF, liver 
function tests, 
CD4/CD8 (death 
keratinocytes)
Activity of IgM 
vs. herpes virus, 
Epstein-Barr, and 
cytomegalovirus 
(CMV)
Patch tests [Pichler]
IVd T cells, IL8, CXCL8 
cells Neutrophils 
Inflammation
Acute generalized 
exanthemic 
pustulosis (AGEP) 
pharmacodermias 
associated with 
neutrophilia
CBC T cells CD4/
CD8
Patch tests [Pichler]
Hypersensitivity reactions require that the individual has been previously sensitized or exposed at least once to the 
antigens in question. The classification of allergic or hypersensitivity reactions into four types (I, II, III, and IV) and 
subsequently Pichler in 2003 proposed the subdivision of type IV into IVa, IVb, IVc, and IVd [27–29].
Table 1. 
Hypersensitivity classification according to the Gell and Coombs modified by Sell, Pichler, and ICON.
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The prolongation of eosinophilia can cause tissue damage, although without 
being clarified specifically, adding to the condition infections as another factor that 
preserves eosinophilia (parasitic and fungal infestations) or decreases (eosinopenia 
due to bacterial and viral infections). The diagnosis can be complicated because of 
the presence of the drug which worsens a preexisting eosinophilia, particularly in 
atopic patients [33].
DRESS is more common in adult patients than in children, with approximately 
50 drugs being described, highlighting anticonvulsants (phenytoin, phenobarbital, 
and carbamazepine) and antibiotics as the main causes of the syndrome and, to a 
lesser extent, sulfate derivatives, antidepressants, NSAIDs, and antidiuretics [34]. 
There is no clear association between variability of the type of drug and the affected 
organ with the degree of eosinophilia, which can be mild or self-limited and severe 
when multisystemic complications are generated due to the presence of symptoms 
that are not appreciated in the mild form [32, 33].
Other proposals that lead to the pathogenesis of DRESS include detoxification 
defects at the time of the formation of reactive metabolites, slow acetylation, and 
reactivation of the human herpes virus (HHV-6-7) or EBV [34].
In general, the diagnostic algorithm for eosinophilia linked to SCAR can be 
visualized as a hypersensitivity response type IVb (SJS and NET) and type IVc 
(DRESS), which in some way can highlight the pathogenesis proposals previously 
mentioned not only by DRESS but identify an atopic patient (Table 1).
5. Conclusions
Eosinophils are leukocytes (white blood cells) found in the peripheral 
blood, hematopoietic, lymphatic organs, thymus, connective tissue, and diges-
tive tract. They are identified and quantified by manual counting (Neubauer 
chamber), automated count with autoanalyzer hemocytometers (impedance, 
colorimetry, and differential in optical microscope), flow cytometry after the 
advent of monoclonal antibodies, currently the most used to identify surface 
markers and immunoenzymatic methods (ELISA, RAST, IMMUNOCAP) for 
cytoplasmic granules.
The classification of eosinophilic diseases “eosinophilic disorders” was revised in 
2008 and confirmed in 2016; its study focused on external (extrinsic) and internal 
(intrinsic) causes (optimized) and optimized and failed diagnosis by precise and 
timely diagnosis. The algorithms are used and started with the main pillar: The 
clinical history (clinical criteria, anamnesis, and exploitative maneuvers leading 
to clinical laboratory algorithms, with initial, basic, and special tests including 
imaging, tomography, and X-rays to finally improve the prognosis and modify the 
natural history. The intrinsic and extrinsic disorder algorithm planting is different; 
this is due to the recognition of molecular altered T cell clones, bone marrow stud-
ies, and markers of apoptotic genes, PCM1-JAK2, Fas L, and bcl2.
Some allergies to medications with symptomatology related to specific organ 
and severe cutaneous against antiepileptics (phenytoin, phenobarbital, carba-
mazepine) as well as other medications (antibiotics, NSAIDs, antidiuretics) can 
be related, which rethinks the proposed immunological response algorithm not 
only in basophil evaluation but also the search for eosinophils in flow cytometry 
or optical microscopy to assess not only damage but neutralization (eosinophil 
histaminase).
Corticosteroids are considered the first line of treatment because of their potent 
anti-eosinophilic effect for disease control, prognosis, and prevention. So the new 
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treatment alternatives could displace steroids with monoclonal antibodies such as 
the IL-5 inhibitor that show less long-term toxicity.
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Appendices and nomenclature
AEC absolute eosinophil count
HSR hypersensitivity reaction
SCAR severe cutaneous adverse reaction
SJS Stevens-Johnson’s syndrome
TEN toxic epidermal necrolysis
DRESS drug rash eosinophilia and systemic symptoms
CBC complete blood count
DHRs  drug hypersensitivity reaction
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